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Abstract     
New methods for O-tosylation of the natural Cinchona alkaloids have been discovered as a 
biphasic processes with Bu3N as a catalyst. The optimized excess of tosyl chloride, necessary for 
transformation of each of the four alkaloids into O-tosyl derivative, decreases in the following 
order: quinine, quinidine, cinchonidine and cinchonine. The same decreasing order has been 
noticed for the hydrolysis rate of the appropriate tosylates to 9-epibases. Difficult conversion of 
O-tosylcinchonine in the hydrolytic medium of aqueous tartaric acid gives 9-epicinchonine 
together with parallel formation of cinchonicine enol tosylate. The latter product is obtained as 
the main when both cinchonine and cinchonidine tosylates react in the presence of salicylic acid 
under controlled microwave heating. On the basis of X-ray structure of the new alkene product, 
the stereoselective syn-E2 quinuclidine ring opening process, competing to the SN2 hydrolysis is 
postulated for this transformation.  
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Introduction    
 
Molecular diversity of the four main natural Cinchona alkaloids: quinine 1a, quinidine 1b, 
cinchonidine 2a and cinchonine 2b (Scheme 1) results in their various biological activity.
1,2
 The 
Cinchona alkaloids and their derivatives are highly useful as chiral ligands and catalysts for a 
wide variety of asymmetric synthesis.
3,4
 The natural molecules are diastereomeric erythro-1,2-
aminoalcohols,
5.6 
while the Cinchona 9-epibases 1c,d and 2c,d, first discovered by Rabe,
7
 are 
threo diastereomers which do not possess medicinal value.
8
 Steric and structural effects are 
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important for biological activity and chemical reactivity of Cinchona alkaloids and play the key 
role in various catalytic induction of chirality in asymmetric syntheses.
9 
Recently, C9-O-derivatives of Cinchona alkaloids have attracted considerable attention, as 
they have the functional group that introduces steric hindrance between quinuclidine and 
quinoline moieties and modifies polarity that is lower than in the original alkaloids.
10
 The 
hydrolysis of the O-tosyl compounds 3a,b, and 4a,b as derivatives of natural erytro-
aminoalcohols 1a,b and 2a,b, leads to 9-epibases 1c,d (for 1a,b) and 2c,d (for 2a,b) with 
inverted C9 configuration and threo configuration in the area of C8-C9. This reaction was first 
conducted by Suszko and co-workers almost eighty years ago.
11-13
 They discovered that the weak 
acid was the only proper aqueous medium for hydrolysis of  O-tosyl Cinchona alkaloids, 
however, it was not efficient for synthesis of 9-epicinchonine 2d by this way. They described 
slow hydrolysis of O-tosyl cinchonine 4b and incomplete conversion of its sulfonate group.
13
 In 
more recent investigations of the Hoffmann group, many side processes have been observed in 
various conditions directed to hydrolysis of 4b. It has been established that the efficient method 
for C9 epimerization of the natural Cinchona alkaloids is the weak acid hydrolysis of their O-
mesyl derivatives, where steric effects lose their significance.
5b,14
 However recently, the 





Scheme 1. Transformation of the natural Cinchona alkaloids 1a,b (8S,9R), 2a,b (8R, 9S) into 9-epibases 
1c,d, (8S,9R), 2c,d (8R,9R) via O-tosyl derivatives 3a,b, 4a,b: (i): retention of C9 in O-tosylation with 
TsCl , (ii): inversion of C9 configuration in hydrolysis of tosylates in the weak acid medium.  
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As a continuation of our work on the structure-properties relationship of Cinchona alkaloids,
16 
we report here the new method of synthesis of O-tosyl derivatives 3a,b and 4a,b with the stress 
on research of their reactivity differences in the hydrolysis to 9-epibases 1c,d, and 2c,d. 
 
 
Results and Discussion 
 
New synthesis of O-tosyl Cinchona alkaloids  
The tosylation methodologies were gradually improved. Long ago, two methods with an excess 
of tosyl chloride were used for O-tosylation of the Cinchona alkaloids.
11-13
  In the first of them, 
alkaloid 1a or 1b reacted in the biphasic system of benzene-aqueous 50% KOH solution. In the  
second method, less soluble 2a or 2b reacted with TsCl in the pyridine medium. Next, O-
tosylation was performed via a two-step procedure: formation of alcoholates with strong base 
(NaH, or BuLi), followed by reaction with tosyl chloride.
16d,17
 Recently, Cinchona alkaloid 




In our initial experiments we tested reaction of Cinchona alkaloids without external tertiary 
amine, with an excess of tosyl chloride in the vigorously stirred biphasic system dichloromethane 
– aqueous KOH. We observed slow transformation to the appropriate tosylate (TLC control). 
Next, triethylamine was added to the reaction mixture and considerable increase in the 
conversion rate was noticed. Then, we chose tributylamine as an effective interface transfer 
agent for the room-temperature O-tosylation. Finally, we examined tributylamine in the catalytic 
quantity in two biphasic systems: liquid-liquid (dichloromethane–aqueous 35% KOH in method 
A); and liquid-solid (dichloromethane–solid powdered anhydrous KOH in method B).  
We propose a mechanism with an inter-phase transfer of reagents in O-tosylation. Tosyl 
chloride interacts with Bu3N and gives a N-tosyl tributylammonium chloride, which can retain in 
the organic phase and acts as a tosylation agent for hydroxy function of the alkaloid (Scheme 2). 
Tributylamine has a role similar to pyridine in conventional acylation and sulfonylation 
processes of alcohols and amines in the pyridine medium, However in this case it is effective 
enough in the catalytic amount, since its protonation in the tosylation process can disappear in 
contact with the aqueous alkaline phase. 
However, two ineffective phase interaction processes can run in parallel to O-tosylation a) 
tosyl chloride may be consumed when it is changed into tosylate anion and transferred from the 
organic phase to the aqueous phase, b) tosyl ester group of the product can be attacked by 
hydroxyl anion, turning back the main process of O-tosylation. These two side processes give 
excessive consumption of tosyl chloride during O-tosylation and therefore it must be used in 
excess. We have optimized the necessary excess of tosyl chloride for each alkaloid 1a,b, and 
2a,b in order to maximize the yields of the corresponding O-tosylates in the experimental scale 
of 10 milimoles of starting materials (Table 1). 
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Scheme 2. Liquid-liquid O-tosylation of quinidine (R=OMe) and cinchonine (R=H) with Bu3N 
as a catalyst. 
 
Table 1. Comparison of optimized amounts of  TsCl needed for conversion of 1a,b and 2a,b into 
3a,b and 4a,b by Method A
a
 , product polarity values  (as Rf  values) and yields 
Started alkaloid
b 
TsCl (mmol) Tosylate number Tosylate Rf
c
 Tosylate yield (%)d 
1a 40 3a 0.85 80 
1b 35 3b 0.58 76 
2a 25 4a 0.62 82 
2b 20 4b 0.55 90 
a
Method A: substrate 10 mmol was stirred with TsCl in the medium of dichloromethane-aqueous 





were measured in ethyl acetate-methanol system 10:1. 
d
After isolation by column 
chromatography. 
 
It is interesting to note that:  
(a) The autocatalytic activity of quinuclidine nitrogen in the Cinchona alkaloid substrates is not 
sufficient for the O-tosylation process, which is significantly slower without tributylamine, the 
reaction time is noticeably longer and much higher excess of tosyl chloride is necessary. 
(b) We found that for the synthesis of O-tosylcinchonine 4b by our Method A, double excess of 
tosyl chloride is sufficient, whereas for the preparation of O-tosylquinine 3a fourfold excess of 
tosyl chloride is necessary. The excess of TsCl needed for synthesis of corresponding O-tosyl 
derivatives decreases in the following sequence: quinine, quinidine, cinchonidine, cinchonine.  
(c) As a result of our investigation of Method B, that consisted in the solid KOH-organic solvent 
tosylation of Cinchona alkaloids in the presence of Bu3N as a catalyst, we found that only the 
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50% excess of tosyl chloride is sufficient for each alkaloid to transform into its corresponding 
tosylate in yield 70-80% together with unchanged alkaloids (TLC control). 
d) Both of our phase transfer methods used for Cinchona alkaloid O-tosylation are processes 
which can be performed at the room temperature, giving yields comparable to those obtained in 




Examination of O-tosyl Cinchona alkaloids’ hydrolysis 
The structure-reactivity relationship was observed during hydrolysis of the four tosylates in a 
diluted solution of tartaric acid in hot water. This is shown in Table 2, Entry 1-4, as different 
reaction times necessary for full conversion of compounds 3a,b and 4a,b. Molecules with the 
methoxy group, i.e. 3a and 3b react easily (15 min and 30 min), giving correspondingly 9-
epiquinine 1c and 9-epiquinidine 1d as the main product, with a small amount of regenerated 
starting alkaloid 1a and 1b. Cinchonidine tosylate 4a reacts slowly to 2c (6 h, Entry 3), but with 
a good selectivity. The 9-epibases 1c, 1d and 2c can be obtained by this way in the preparative 
scale with good yields in the purity above 98% (determined by 
1
H NMR after isolation by the 
column chromatography). However, hydrolysis of cinchonine tosylate 4b runs much slower (20 
h, Entry 4), giving the mixture of three products. When we applied careful column 
chromatography with methoxethanol, a trace of regenerated cinchonine 2b (Rf=0.47) was 
isolated first. Then, a new compound 5 possessing lower polarity (Rf =0.39) was collected. Next, 
9-epicinchonine 2d (Rf=0.31) was eluted with the mixtures of 2-methoxyethanol and methanol. 
The new product 5 was identified by spectral data as a product of quinuclidine ring cleavage in 
the intramolecular piperidine elimination (Scheme 3), and can be called cinchonicine (or 
Pasteur’s cinchotoxine) enol tosylate. Microwave enhancement of the hydrolysis of 4b (Table 2, 
Entry 5) gives the equal amounts of both 2d and 5. We discovered that the latter compound is 
formed as the main product (Scheme 3) when cinchonine tosylate 4b reacts with the excess of 
salicylic acid in a medium of water/ethylene glycol under controlled microwave heating (Table 
3, Entry 6).  
In the next step of our experiments we found that the same cinchonicine enol tosylate 5 can 
also be obtained as the main product (together with epicinchonidine 2c and cinchonidine 2a) 
from O-tosylcinchonidine 4a irradiated by microwaves with an excess of salicylic acid (Table 2, 
Entry 7). However, in this case, it is difficult to separate pure 5 from the reaction mixture since 
its Rf  value (0.39) is near to the Rf  value observed for 9-epicinchonidine 2c (0.35) 
We were the first to observe that the Pasteur’s type cleavage of O-tosylcinchonine 4b occurs 
in the hydrolytical medium, leading to formation of the new compound, cinchonicine enol 
tosylate 5. We have found out that this process is competing to hydrolysis of O-tosylcinchonine 
4b in conventional conditions (diluted aqueous tartaric acid), and that it is the main reaction 
under controlled microwave heating of both 4b and 4a with an excess of salicylic acid in the 
ethylene glycol-water medium.  This type of transformation is similar to the Pasteur’s cleavage 
of the natural Cinchona alkaloids to cinchotoxine (ketone) when they are heated with organic or 
mineral acids.
5,6
 Toxine rearrangement of Cinchona alkaloids with acetic acid in the presence of 
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acetic anhydride has been investigated,
18
 and the cinchonicine enol acetate formation has been 
postulated. However, this compound, similar to 5, has not been isolated so far.  
 
Table 2. Yields and Rf  values of 9-epibases 1c,d and 2c,d obtained in different conditions from 






Tosylate hydrolysis Reaction products 





1 1a [0.63] 3a 15 min
c 
1c 0.39 75 
2 1b [0.61] 3b 30 min
c 
1d 0.46 65 
3 2a [0.54] 4a 6 h
c 
2c 0.35 70 
4 2b [0.47] 4b 20 h
c 
5 + 2d 0.39; 0.31 15; 45 
5 2b [0.47] 4b 20 min
d 
5 + 2d 0.39; 0.31 30; 30 
6 2b [0.47] 4b 30 min
e 
2b+5+2d 0.47; 0.39; 0.31 15; 60; 15 
7 2a [0.54] 4a 15 min
e
 2a+5+2c 0.54; 0.39; 0.35 10; 40; 20 
a 
Values of Rf  were measured on silica-gel TLC plates in 2-methoxyethanol. 
b 
Yields of product 
isolated by column chromatography. 
c 
Procedure 1: Tosylate (10 mmol) was heated at 92-95 ºC 
with the aqueous solution of tartaric acid (15 mmol: 0.1M, 150 ml). 
d 
Procedure 2:  Tosylate 4b 
(4 mmol) was added to 20 mL of water containing tartaric acid (6 mmol) and was irradiated in an 
open vessel (Synthewave 402 reactor, Prolabo) at the controlled temperature of 95 ºC. 
e 
Procedure 3: Tosylate 4b or 4a (2 mmol) and salicylic acid (20 mmol) were added to 20 mL of 
50 % ethylene glycol water solution and irradiated in an open vessel (Synthewave 402 reactor, 




Scheme 3. Possible ways of transformation of 4b-H
+
 in the syn-open conformation: hydrolysis with C9 
inversion to 2d or with retention to 2b (by H2O attack at the C9 or at the sulfur of sulfonate) versus H-C9 
elimination together with N1-C8 bond cleavage towards the cinchonicine enol tosylate 5, which  is next 
converted to sulfonamide 6. 
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The sulfonamide derivative 6 preparation for crystal and molecular structure 
determination by X-ray diffraction 
The 
1
H NMR spectrum of the new product 5 shows a signal picture proper for four alkene 
protons (5.0-6.2 ppm), where three of them display the vinyl group. The signal of the new enol-
alkene proton is visible as a triplet at 5.75 ppm. It is interesting that each of the four piperidine 
protons bonded with -carbons (2.50-3.20 ppm) gives separated signal, which means that only 
one conformation of piperidine can exist as dominant. Therefore, axial and equatorial protons do 
not give the average signals. The piperidine ring conformation with the large 4-substituent in 
equatorial position seems to be most probable. However, we cannot determine the enolane 
geometry from 
1
H NMR as the NOE effects were observed as unclear. 
The product 5 is in an oily form. We decided to transform it into sulfonamide derivative 6 in 
reaction with tosyl chloride in the presence of BuEt3 (Scheme 3). The crystals appropriate for the 
X-ray experiment were obtained after purification by column chromatography and slow 
evaporation of aqueous-ethanol solution.  
 
Figure 1. Ortep drawing of 6 with displacement ellipsoids shown at the 30% probability level 
(left) and intramolecular interaction (right), where the red ball shows the center of the O-tosyl 
aromatic ring. 
  
As shown in the projections of the molecule of the compound 6 (Figure 1), the configuration 
Z should be assigned to the double bond C8=C9. The shape of the molecule seems to be 
determined by the intramolecular C-H···π interactions (e.g. the distance C6-H··· π = 2.762Å) 
which are most probably responsible for the conformation of the whole molecule.
19
 The aromatic 
ring of the tosylate group and the quinoline ring are almost planar and almost parallel to each 
other, the angle between their planes being about 8°. The N-tosyl moiety is strongly deviated 
from the O-tosyl group (the angle between the two planes equals 56°). The classical 
intermolecular hydrogen bonds do not exist in the crystal structure of the compound 6, however 
the weak hydrogen bonds, C-H···O can play a crucial part in controlling the crystal packing (see 
Supplementary Material). 
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Comparative conformational analysis of N-1 protonated forms of 4a and 4b as a method 
explaining potential formation of transition states towards hydrolysis to 9-epibases versus 
intra-molecular elimination to 5. 
The course of hydrolysis of O-tosyl derivatives 4a and 4b with the inversion of configuration at 
C9 must occur as the SN2 nucleophilic attack of water molecule on the side opposite to the 
tosylate leaving group in the substrate protonated at the quinuclidine nitrogen. Theoretical 
considerations assume four energetically possible conformers of Cinchona alkaloid molecules:
9a
 
two closed (anti and syn) and two open (anti and syn). The syn-open conformation of O-tosyl 
cinchonine 4b is the most required for 9-epicinchonine 2d formation (see Scheme 3).  
Recently, we have published results of the X-ray structure analysis and theoretical 
calculations of the diastereoisomeric molecules 4a and 4b, which were used to explain their 
different reactivity in the hydrolysis to the respective 9-epibases.
20
 The differences in energetic 
profit during protonation on N1 atom and in propensity to the conformation change from an anti-
closed in the crystals of both neutral molecules to a syn-open one, favored in their weak acid-SN2 





epibases. Now, we will tray to elucidate why the competing process occurs towards the cleavage 
of quinuclidine ring leading to cinchonicine enol tosylate 5 formation.  
On the Scheme 4 can be seen the possibility of easy rotations in molecule 4a
+
-H around C8-
C9 bond (giving closed and open conformers), as well as around C4’-C9 bond (giving syn and 
anti conformers). The hydrolysis can run as the attack of water molecule at C9 atom in both open 
conformers Ca3 and Ca4. This creates the possibility for the transition state formation that gives 
9-epicinchonidine 2c. The regioselectivity towards 2c can be experimentally observed in the 
classical heating of 4a with aqueous tartaric acid. This indicates that the SN2 process runs under 
kinetic control, that requires accessibility of the rotamers Ca3 and Ca4 as the energetically 
privileged. The experimental result shows that the microwave activation of the protonated 
molecule leads to the formation both of 2c and 5. This fact indicates that the syn-E2 cleavage 
process, competing to SN2 hydrolysis, cannot be conformationally determined. It is forced by the 
internal microwave activation of 4a-H
+ 
molecule, which can react without conformational 
preference. In this case, high energetic demand for transition state formation requires 
simultaneous interaction of the anionic-base (A
-
) with quinuclidine cationic nitrogen 
(electrostatic) and the proton H-C9 (acid-base). Theoretical conformational analysis shows that 
this is possible in all the open and closed conformers (Scheme 4). Moreover, the experiments 
revealed that the preference towards elimination to 5 can be achieved under microwave 
irradiation of 4a-H
+ 
 with the salicylic acid in the aqueous medium.  
 In the view of considered ways of microwave activation in different types of organic 
syntheses,
21
 the contribution of microwave catalysis through rotationally hot reactive species
22 
is 
the most probable reason for the emergence of the second direction of 4a
+
-H transformation 
towards 5 formation by the cleavage of quinuclidine ring. This none-quilibrium system can be 
formally described by considering of rotational temperature, which is higher than the 
translational temperature for the all existing closed and open conformers.  
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Scheme 4. Hypothetical ways of 4a
+
-H hydrolysis towards formation of 2c and 5. 
   
In the case of the protonated molecule of O-tosyl cinchonine 4b
+
-H (Scheme 5), the vinyl 
group is a tethered element that determines possible rotations. There are difficulties in the 
rotation around bond C8-C9 that change the closed conformers (Cb1 and Cb2) into more hindered 
open conformers (Cb3 and Cb4). Due to high energetic barrier of rotations, the transition state for 
the attack of the water molecule on the carbon atom C9 in SN2 hydrolysis that leads to 9-
epicinchonine 2d, is difficult to achieve. This is the reason for O-tosyl cinchonine 4b hydrolytic 
stability in the weak acid medium.  
The discussion of conformations leads to the conclusion that in this case a competing 
reaction with the acid anion as a base can lead to the intramolecular syn-E2 elimination to the 
alkene 5 possessing the same geometry as that obtained from 4a-H
+
. This product can form 
without conformational preference and was observed both in the prolonged conventional heating 
of 4b-H
+
 (Entry 4, Table 2) and under short microwave irradiation at the temperature of 95ºC. 
The excess of the salicylic acid with the microwave activation leads to prevailing conversion into 
the cleavage product 5. However, in this case, considerable amount of cinchonine 2b with the 
retention of C9 configuration is parallel formed in the course of hydrolysis. It is possible in result 
of the O-SO2 bond cleavage after water molecule attack on the sulfonate group of 4b
+
-H.  
The stereoselectivity that we observed, lead to formation of Z-alkene 5 from tosylates 4a and 
4b, which confirms that this is the second type of mechanism (three types are mentioned in 
the literature: ref
4
 pp. 361-363) for the Pasteur cleavage of natural Cinchona alkaloids giving 
ketone via enol. The fact that the intramolecular piperidine elimination is more plausible when 
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the planar salicylate anion (A
-
) takes part as a base, instead of the tartrate anion, can be 





Scheme 5. Conformational analysis of 4b in the aspect of the two routes of its transformation: 
intramolecular elimination to 5 and the difficult SN2 hydrolysis to 2d. 
 
 
Conclusions   
  
We have developed the new methods for the effective and selective transformation of the four 
natural Cinchona alkaloids into appropriate O-tosyl derivatives at room-temperature in biphasic 
systems using tributylamine as the catalyst. The tosyl esters has been carefully reinvestigated in 
the hydrolysis-inversion process leading to 9-epibases 1c,d and 2c,d. We confirm that the 
molecules with the methoxy group 3a,b are significantly more reactive than cinchonidine and 
cinchonine tosylates 4a and 4b. The latter one is the most hydrolytically stable in the substitution 
process by the water molecule in the weak-acid aqueous medium. Comparative conformational 
analysis for cinchonidine and cinchonine tosylates 4a and 4b has been employed for the 
explanation of this phenomenon. We have found that the vinyl group can take part in the  
tethering effect inside molecule 4b
+
-H and it can prevent rotation that leads to conformation 
necessary for hydrolysis in the aqueous acid medium. Therefore, this molecule is less prone to 
SN2 hydrolysis and it reacts in the Pasteur-type quinuclidine ring cleavage process leading to the 
new derivative, cinchonicine enol tosylate 5. (Z)-Alkene geometry is determined on the basis of 
the X-ray structure of the sulfonamide 6 as derivative of 5. Therefore the stereoselective syn-E2 
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of quinuclidine ring-opening process, competing to the SN2 hydrolysis is postulated for the 
formation of the product 5. This product is almost selectively formed from cinchonidine or 
cinchonine tosylates (4a or 4b) with salicylic acid solution under controlled microwave 
irradiation and can be synthesized by this route in the preparative scale. The new compound is 
the chiral alkene and can be used as building block
23
 for asymmetric synthesis, including chiral 





Experimental Section     
 
General. Commercial Cinchona alkaloids from Fluka were used. Other reagents and solvents 
were purchased from commercial suppliers (Sigma-Aldrich) and used without further 
purification. The course of reactions was monitored by thin-layer chromatography (aliquots were 
taken and extracted by ethyl ether in the presence of ammonia), which was carried out on 0.25 
mm Merck silica gel (60 F254) plates on aluminium. Pure products were isolated by CC over 
Merck silica gel 60 (230-400 mesh). The column output was monitored with TLC (on aluminium 
sheets precoated with silica gel 60254, Merck). Melting points (uncorrected) were determined on 
the Bëthius apparatus. The optical rotations were measured on a Perkin Elmer 241 polarimeter. 





C NMR spectra were recorded with MERCURY 400 BB or VARIAN 400MR 
spectrometer (
1
H; 400 MHz, 
13
C: 100 MHz). Chemical shifts are given relative to TMS (δ=0) in 
ppm and refer to residual solvent as internal standard.  All compounds were determined to be > 
96 % pure by 
1
H NMR analysis. IR spectra (KBr pellets) were recorded on FT-IR MAGNA 769 
(Nicolet). 
 
General procedure for the Method A tosylation exemplified by the synthesis of 4b 
Tosyl chloride (3.81 g, 20 mmol), tributylamine (0.25 mL, 1 mmol) and 35% potassium 
hydroxide aqueous solution  (50 mL) were added to a stirred solution of cinchonine 2b (2.94 g, 
10 mmol) in dichloromethane (150 mL). The resulting mixture was stirred at 20ºC for 24 h (the 
monitoring of cinchonine conversion on silica gel TLC plates with a mixture of ethyl acetate and 
methanol 10:1). Then water (100 mL) was added and stirred for 10 min. The organic phase was 
separated and washed by water (3 x 50 mL) and extracted with cold 1M hydrochloric acid  (5 x 
25 mL). The aqueous phase was washed with diethyl ether (3 x 25 mL) and then 2N NaOH was 
added until pH > 10. The mixture was extracted with dichloromethane (4 x 50 mL) and the 
combined organic extracts were washed with water (2 x 30 mL) and dried with Na2SO4. The 
solvent was evaporated under reduced pressure and crude product 4b; 4.25 g, 95.0 %  
(containing a trace amount of starting alkaloid 2b, TLC indicated), as white precipitate was 
obtained. After column chromatography with ethyl acetate-methanol 20:1,.pure 4b 4.03g, 90 % 
was obtained.  
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O-tosylcinchonine (4b) M.p. 174-175 ºC, [ ]D
27
 +35.9 º  (c 1.00, in EtOH anhyd,); (lit.
11a
 m.p. 
173 ºC, [ ]D
20
  +51 º (c 1 in 96 % EtOH); IR (KBr) cm
-1
: 3069, 2939 2867, 1635, 1592, 1511, 
1454, 1363 (SO2), 1242, 1189, 1174  (SO2), 1095, 1058, 1021, 987, 935, 870, 811, 760, 667, 
555; 
1
H NMR (400 MHz, CDCl3) δ (ppm): 8.68 (d, 
3
J = 4.4 Hz, 1H, H-2’), 7.98 (d, 
3
J = 7.6 Hz, 
1H, H-8’), 7.97 (bs, 1H, H-5’), 7.67 (t, 
3
J = 7.6 Hz., 1H,  H-7’), 7,51 (t, 
3
J = 7.6 Hz, 1H,.H-6’), 
7.33 (d,  
3
J = 7.2 Hz, 2H, H-2”, H-6”), 7.21 (bs, 1H, H-3’), 6.78 (d, 2H, 
3
J = 7.2 Hz, H-3”, H-5”), 
6.10 (bs, 1H, H-9), 5.98 (ddd, 
3
J = 17.6, 10.6, 7.7 Hz, 1H, H-10), 5.12-5.05 (m, 2H. H2-11), 3,30 
(s-br, 1H, H-8), 2.82-2.76 (m, 2H, H-2, H-6), 2.64-2.56 (m, 2H, H-2, H-6), 2.28-218 (m, 1H, H-
3), 2.16 (s, 3H, H3CAr), 1-92-1.84 (m, 1H H-5), 1.84-1.78 (m, 1H, H-7), 1.76-1.65,m, 1H, H-4), 
1.54-1.48 (m, 2H, H-5. H-7); 
13
C NMR (100 MHz, CDCl3) δ: 149.4 (C-2’), 148.1, (C-4’), 144.5 
(C-9’),  143.9 (C-4”), 139.9 (C-10), 132,9 (C-1”), 130,2 (C-3”, C-5”), 129.0 (C-8’),  128.8 (C-
7’), 127,5 (C-2” and C-6”), 126.7, (C-6’) 125.5 (C-10’), 122.9 (C-5’), 119.5 (C-3’), 114.9 (C-
11), 76.2 (C-9), 60.3 (C-8), 49.6 (C-2), 48.7 (C-6), 39.7 (C-3), 27.6 (C-7), 26.2 (C-5), 24.5 (C-4), 
21.3 (H3CAr).  
The products 3a, 3b and 4a are obtained from 1a, 1b and 2a with tosyl chloride in the excess  
given in Table 1 (together with Rf  values of products). Their physicochemical and spectral data 
are reported below. 
 
O-tosylquinine (3a). Crude (92 %), an oily form; pure (80 %), m.p. 58-60 ºC, [ ]D
27
 +11.7º (c 
1.00 in 99.8 % EtOH); (lit
12
 oil, [ ]D
21 
+9.8º (c 1.02 in 96.0 %  EtOH);  IR (KBr), cm
-1
: 3071, 
2938, 2867, 1621, 1596, 1508, 1475, 1453, 1362 (SO2), 1304, 1263, 1226, 1186, 1175 (SO2), 
1091, 1029, 989, 930, 919, 862, 811, 766, 668, 569, 550; 
1
H NMR (400 MHz, CDCl3) δ (ppm): 
8.51 (d, 
3
J = 4.4 Hz, 1H, H-2’), 7.86 (d, 
3
J = 9.2 Hz, 1H, H-8’), 7.31-7.25 (m, 3H, H-7’, H-2”, H-
6”), 7.15 (bs, 2H, H-3’, H-5’), 6.76 (d, 
3
J = 7.2 Hz, 2H, H-3”, H-5”), 6.10 (bs, 1H, H-9) 5.81 
(ddd, 
3
J = 17.2, 9.8 7.4 Hz, 1H, H-10), 5.02-4.95 (m, 2H, H2-11), 3.93 (s, 3H, MeO), 3.30 (bs, 
1H, H-8), 3.14-3.05 (m, 1H, H-6), 2.98-2.90 (m, 1H, H-2), 2.64-2.56 (m, 1H, H-2), 2.54-2.46 (m, 
1H, H-6), 2.28-2.20 (m, 1H, H-3), 2.15 (s, 3H, Me-Ar), 1.92-1.86 (m, 1H, H-4), 1.79-1.60 (m, 
2H, H-5, H-7), 1.58-1.42 (m, 2H, H-5, H-7). 
13
C NMR (100 MHz, CDCl3) δ (ppm): 157.8 (C-6’), 
146.9 (C-2’), 144.5 (C-4’), 1.44.3 (C-4”), 141,9 (C-9’), 141.6 (C-10), 133.7 (C-1”), 133.0 (H-8’). 
131.6 (H-3”, H-5”), 128,8 (H-8’), 127.4 (C-2”, C-6”), 126.5 (C-10’), 121.6 (H-3’), 118.8 (H-7’), 
114.4 (C-12), 100.4 (C-5’), 79.7 (C-9), 60.3 (C-8), 56.3 (C-6), 55.9 (H3C-O), 42.3 (C-2), 39.5 
(C-3), 27.4 (C-5), 27.2 (C-7), 25.0 (C-4), 21.3 (H3CAr.). 
O-tosylquinidine (3b). Crude; (85 %), oily; pure (76 %), m.p. 119-120 ºC; [ ]D
27
 +23.5º (c 1.00 
in 99.8 % EtOH); (lit.
12
 m.p. 116–118 ºC [ ]D
21
 +28.3º (c 1.02 in 96.0 % EtOH);  IR (KBr), cm
-1
, 
3072, 3011, 2935, 2869, 1621, 1596, 1509, 1475, 1454, 1364 (SO2), 1302, 1225, 1189, 1176 
(SO2), 1090, 1027, 989, 918, 856, 818, 764, 666, 570, 550; 
1
H NMR (400 MHz, CDCl3) δ: 8.53 
(d, 
3
J = 4.4 Hz, 1H, H-2’), 7.88 (d, 
3





= 9.2 Hz, 
4
J = 2.0 Hz, 1H, H-7’), 7.15 (d, 
3
J = 7.6 Hz, 2H, H-2”, H-6”), 6.82 (d, 
3
J = 7.6 
Hz, 2H, H-3”, H-5”), 6.13 (bs, 1H, H-9), 5.97 (ddd, 
3
J = 17.2, 10.8, 7.2 Hz, 1H, H-10), 5.12-505 
(m, 2H, H2-11), 3,93 (s, 3H, H3C-O), 3.20 (bs, 1H, H-8), 2.87-2.77 (m, 2H, H-2, H-6), 2.68-2.57 
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(m, 2H, H-2, H-6), 2.29-219 (m, 1H, H-3), 2.17 (s, 3H,.H3CAr), 1.96-1.85 (m, 1H, H-4), 1.83-
1.78 (m, 1H, H-5), 1.72-158 (m, 1H, H-7), 1.54-1.47 (m, 2H, H-5. H-7); 
13
C NMR (100 MHz, 
CDCl3) δ: 157.7 (C-6’), 146.9 (C-4’), 144.6 (C-2’), 144.3 (C-1”), 142.5 (C-9’), 140.0 (C-10), 
133.0 (C4”), 131.6 (C3”, C5”), 128.9 (C8’), 127.5 (C2”, C6”),  126.6 (C10’), 121.6 (C3’) 118.7 
(C-7’) 115.0 (C-11), 100.4 (C-5’), 79.4 (C-9), 60.5 (C-8), 55.4 (H3CO), 49.7 (C-2), 49.0 (C-6), 
39.7 (C-3), 27.6 (C-5), 26.22 (C-7), 23.9 (C-4), 21.3 (H3CAr). 
O-tosylcinchonidine (4a). Crude (91 %) m.p. 125-127 ºC, pure (82.0 %), m.p. 134-135 ºC, 
[ ]D
27




 +3.1º (c 0.03, 96.0 % EtOH);   IR (KBr) cm
-
1
: 3071, 2968, 2941, 2870. 1621, 1596, 1511, 1455, 1433, 1361 (SO2), 1263, 1190, 1173 (SO2), 
1096, 1030, 1018, 989, 930, 868, 804, 759, 672, 572; 
1
H NMR (400 MHz, CDCl3), δ: 8.66 (d, 
3
J 
= 4.0 Hz, 1H, H-2’), 7.98 (d,  
3
J = 8.0 Hz, 2H, H-5’, H-8’), 7.67 (t, 
3
J = 8.3 Hz, 1H. H-7’), 7,56-
7.48 (m, 1H, H-6’), 7.29 (d, 2H, 
3
J = 7.7 Hz, H-2”, H-6”), 7.19 (bs, 1H, H-3’), 6.73 (d, 
3
J = 7.7 
Hz, 2H, H-3”, H-5”), 6.08 (bs, H-9), 5.83 (ddd,  
3
J = 17.6., 10.4, 7.4 Hz, 1H, HC10), 5.02-4.96 
(m, 2H, H2-11), 3,35 (bs, 1H, H-8), 3.12-3.00 (m, 1H, H-6), 2.92 (dd, 1H, 
2
J  = 13.6, 
3
J = 9.4 Hz, 
H-2), 2.56 (ddd,, 
2
J  = 12.6, 
3
J = 10.8, 4.4 Hz, 1H, H-6), 2.51-2.42 (m, 1H, H-2), 2.28-2.20 (m, 
1H, H-3), 2.14 (s, 3H, H3CAr), 2.14-2.0 (m, 1H, H-4), 1.91-187 (m, 1H, H-7), 1.78-1.62 (m, 1H, 
H-5), 1.56-1.48 (m, 2H, H-5, H-7); 
13
C NMR (100 MHz, CDCl3) δ: 150.3 (C-4’), 149.5 (C-2’), 
148.1 (C-9’), 144.5 (C-4”), 141.6 (C-10), 133.0 (C-1”), 130,3 (C-3”, C-5”), 129.1 (C-8’), 128.8 
(C-7’), 127,5 (C-2”, C-6”), 126.7 (C-6’), 125.8 (C-10’), 123.1 (C-5’), 117.5 (C-3’), 114.5 (C-11), 
76.2 (C-9), 60.3 (C-8), 49.6 (C-2), 48.7 (C-6), 39.7 (C-3), 27.6 (C-7), 26.2 (C-5), 24.5 (C-4), 
21.3 H3CAr). 
 
Method B: Solid-liquid phase  O-tosylation: is given in the Supplementary Material. 
Hydrolysis of O-tosyl derivatives by conventional Procedure 1 to 9-eipibases 1c, 1d, 2c, 2d 
and their 
1
H NMR and 
13
C NMR spectra  are given in the Supplementary Material.  
 
General characterization data: for obtained 9-epibases 1c,d, 2c,d are given below.  
9-Epiquinine (1c). Oil, [ ]D
27
 +42.5º (c 1.24, 99.8 % EtOH); {lit.
12
 oil, [ ]D
20
 +50.4º (c 0.442, 




 +39.9º (c 1.13 in EtOH)}. 
9-Epiquinidine (1d). M.p. 114-115 ºC,  [ ]D
27
 +105.5º (c 1.00, 99.8% EtOH); {lit.
12
 m.p. 112-
113 ºC, , [ ]D
2




 +96.3º (c 1.15 in EtOH)}. 
 9-Epicinchonidine (2c). M.p. 109-110 ºC, [ ]D 
27
 + 60.8º (c 1.00, 99.8 % EtOH), {lit.
12
 m.p. 
101-104 ºC,  [ ]D
19
 +69.7º (c 0.80, EtOH 99.5 %) lit.
17b
 [ ]D 
28
 + 56.9º (c 1.15 in EtOH)}. 
9-Epicinchonine (2d). M.p. 89-90 ºC, [ ]D
27









  +114.5º (c 1.07 in EtOH)}. 
 
Procedure 2. Hydrolysis of tosylate 4b under microwave irradiation in the medium of 
tartaric acid is given in the Supplementary Material. 
Procedure 3. Hydrolysis of tosylates 4a and 4b under controlled microwave irradiation in 
the medium of salicylic acid toward cinchonicine enol tosylate 5 formation: Tosylate  4b (or 
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4a) (0.90 g, 2 mmol) and salicylic acid (20 mmol) were placed in a Pyrex cylindrical vessel and 
20 mL of 50 % ethylene glycol was added. The reaction mixture was subjected to microwave 
irradiation at 95 ºC. The full conversion of substrate 4b was observed (TLC, EtOAc-EtOH=10:1) 
after 30 minutes (4a after 15 min). The reaction mixture was extracted with dichloromethane in 
the presence of an excess of cold sodium hydroxide 20 % solution. The organic phase was dried 
with anhydrous sodium sulfate and the organic solvent was removed under reduced pressure. The 
yields and Rf values of products obtained from 4b after CC separation are given in Table 2, entry 
6.  Product 5 (0.54 g, 60 %) was isolated using the mixture methoxyethanol/methanol 5:1) as a 
colorless oil substance: [ ]D
20
 +33.2º (c 1.08 in 99.8% EtOH). 
  
(Z)-1-(Quinolin-4-yl)-3-((3R,4R)-3-vinylpiperidin-4-yl)prop-1-enyl 4-methylbenzene 
sulfonate (5). IR (KBr) cm
-1
 (m-middle, s-strong): 3066 (m), 3030 (m), 2922 (s), 2854 (m) 2802 
(m), 2733 (m), 1693 (m), 1637 (m), 1586 (m), 1506 (s), 1444 (m), 1373 (s, SO2), 1268 (m), 1188 
(s, SO2),  1177 (s), 1092 (m); 
1
H NMR (400 MHz, CDCl3) δ: 8.51 (d, 
3
J = 4.5 Hz, 1H, H-2’), 

















 = 8.2, 7.8, 
4
J = 1.2, 1H, H-7’),  7.45 (ddd, 
3
J  = 8.2 , 7.8, 
4








 = 4.5 Hz, 1H. H-3’), 6.78 (d, 
3
J = 8.2 Hz, 2H- m-SO2Ar), 
6.10 (ddd, 
3
J = 17.0, 10.3, 7.6 Hz, 1H, HC10), 5.75 (t, 
3
J = 7.6 Hz, 1H, H-8), 5.17 (dd, 
3
J  = 
10.3, 
2
J = 2.0 Hz, 1H, H-11), 5.09 (dd, 
3
J  = 17.0, 
3
J = 2.0 Hz, 1H, H-11), 3.09 (ddd, 
2
J = 12.4 
Hz, 
3
J = 3.6 Hz  
3




= 14.8 Hz, 
3
J = 3,4 Hz, 1H, Heqat.-2), 2.83 
(dd, 
2
J = 14.8 Hz, 3.6 Hz, 1H, Haxial-2), 2.65 (ddd, 
2
J = 12.4 Hz, 
3
J = 10.8 Hz, 
3
J = 3.6 Hz, 1H, 
Haxial-6), 2.36-2.20 (m, 3H, H-3, H2-7), 2.17, s, H3CAr 3H), 1.82-1.73 (m, 1H, H-4) 1.68-1.44 
(m, 2H, H2-5), 
13
C NMR (100 MHz, CDCl3) δ: 162.3 (C-9), 150.2 (C-2’), 148.2 (C-9’), 145.6 
(C-1”), 144.8 (C-4’), 141.0 (C-4”), 137.3 (C-11), 130.2 (C-3”, C-5”), 129.9 (C-8’), 129.6 (C-7’), 
127.9 (C-6’), 127.5 (C-2”, C-6”), 126.0 (C-10’), 125.7 (C-5’),  121.8 (C-11), 117.7 (C-2’), 116.5 
(C-8, 51.0 (C-2), 46.7 (C-6), 43.1 (C-3), 39.6 (C-4), 35.1 (C-5), 28.5 (C-7), 21.4 (H3CAr3); 
HRMS (ESI, [M+H]
+
) found: 449.1905, calcd for C26H29N2O3S: 449.1899. 
 
Synthesis of sulfonamide (60). To the solution of 5 (224 mg, 0,5 mmol) in CH2Cl2 (20 mL) 
tosyl chloride  143.0 mg, 0.75 mmol), tributylamine (0,012 mL, 0,05 mmol) and 35 % KOH 
solution (10 mL) were added. Substrate was disappeared in reaction mixture (TLC control) after 
15 min stirring at room temperature. The organic phase was separated and washed by water, 
dried and evaporated. White solid was obtained (283 mg, 94.0 %). After column chromatography 
with using of the ethyl acetate as eluent, pure 6 was obtained  (260 mg, 86.4%), m.p. 154-155 ºC. 
Solid was dissolved in the mixture 1:1 hexane-ethyl ether and was stored to crystallization. 








 = 4.1 Hz, 1H, H-
2’), 7.94 (d, 
3




= 8.6 Hz, 1H, H-5’), 7.63-7.59 (m, 3H, H-7’+ 2 x 
H-o-OSO2Ar), 7.43 (dd, 
3




 = 8.1 Hz, 2H, 2H-o-NHSO2Ar), 
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= 8.1 Hz, 2H, 2H-m-NHSO2Ar), 7.17 (d, 
3




= 8.1 Hz, 
2H, 2H-m-SO2Ar), 6.17 (ddd, 
3
J = 17.2, 10.2, 8.8 Hz, 1H, H-10), 5.65 (t, 
3


















1H, Heqat.-2), 3.58 - 3.55 (m, 1H, Hequat.-6), 2.53 (dd, 
2




= 3.0 Hz, 1H, Haxial-2), 3.44-




= 17.4, 7.7 Hz, 2H, H2-7), 2.15 (s, 
3H, H3CAr), 1.68 – 1.56 (m, 3H, H-4, H2-5). 
13
C NMR (100 MHz, CDCl3) δ: 163.2 (C-9), 149.2 
(C-2’), 147.9 (C-9’), 144.9 (C-1”), 144.3 (HC-4’), 143.4 (C-1”’), 140.2 (C-10), 138.2 (C-4”), 
137.5 (C-4”’), 134.9 (2xC-m-Ar”), 132.9 (2xC-m-Ar”’), 129.5 (2xC-o-Ar”), 129.3 (C-8’), 128.7 
(C7’), 127.5 (2xC-o-Ar”’), 126.9 (C-6’), 126.1 (C-10’) 125.4 (C-5’), 125.2 (C-8), 121.2 (C-3’), 
118.0 (C-11), 50.7 (C-2), 46.0 (C-6), 42.0 (C-4), 38.4 (C-3),  29.3 (C-5), 27.1 (C-7), 21.5 (Ar”-
CH3), 21.2 (Ar-”’CH3). 
 
Supplementary Materials: Additional experimental procedures, X-ray data, 
1
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